Abstract
Anticoagulant therapy is commonly prescribed for both the acute treatment, and long-term prevention of venous thromboembolism (VTE), and as primary and secondary prevention of stroke in the context of atrial fibrillation (AF) [1]. Until recently the majority of patients requiring chronic anticoagulant therapy were prescribed vitamin K antagonists (VKA), as these were the only oral anticoagulant agents available [1]. A requirement for regular monitoring and VKA-drug or-food interactions has meant that not all patients that have an indication for anticoagulation have benefitted from these agents.
Original language | English |
---|---|
Pages (from-to) | 36-38 |
Number of pages | 3 |
Journal | Thrombosis Research |
Volume | 176 |
DOIs | |
Publication status | Published - 12 Feb 2019 |
Keywords
- Apixaban
- Endothelial
- Factor Xa inhibitors
- Nitric oxide
- Rivaroxaban
- Vasodilation
Fingerprint
Dive into the research topics of 'Direct oral anticoagulant (DOAC)-mediated vasodilation: Role of nitric oxide'. Together they form a unique fingerprint.Profiles
-
Greg Scutt
- School of Applied Sciences - Clinical Principal Lecturer
- Centre for Lifelong Health
Person: Academic